Skip to main content

Table 2 Disease measures and treatment in 92 early rheumatoid arthritis patients followed for 10 years

From: Generalized bone loss in early rheumatoid arthritis patients followed for ten years in the biologic treatment era

  Period 0–2 years (n = 92) Period 2–10 years (n = 74) P value
Mean ESR (mm/hr) 21.2 (12.0) 13.2 (6.8) <0.001
Mean CRP (mg/dl) 18.8 (14.9) 8.1 (7.0) <0.001
14.7 [18.0] 5.5 [8.6]
Mean DAS28ESR3 4.17 (0.88) 2.92 (0.82) <0.001
Mean MHAQ (0–3) 0.42 (0.30) 0.27 (0.27) <0.001
0.33 [0.45] 0.18 [0.42]
Ever users synthetic DMARDs 84 (91.3) 66 (89.2) <0.001
Ever users methotrexate 71 (77.2) 61 (82.4) <0.001
Ever users biologic DMARDs 17 (18.5)* 46 (62.6)** <0.001
Ever users prednisolone 57 (62.0) 38 (51.4) <0.001
Ever users any GC*** 76 (82.6) 59 (79.7) 0.400
Mean prednisolone equivalent dose (gram)**** 4.56 (4.71) 7.29 (10.53) 0.012
  2.77 [7.50] 2.09 [11.53]  
  1. Continuous variables with normal distribution are presented as mean with standard deviation (SD) whereas variables with non-normal distribution also are presented as median with interquartile range [IQR]. Categorical variables are presented as numbers and percentage (%).
  2. Calculated from baseline, 6 months and 2 years data.
  3. Calculated from 2 years 5 years and 10 years data.
  4. *All treated with tumor necrosis factor inhibitors.
  5. **All treated with tumor necrosis factor inhibitors, 6 patients also had been treated with other biologic DMARDs (rituximab and/or tocilizumab).
  6. ***Includes prednisolone, intraarticular and intramuscular GC injections.
  7. ****The cumulative doses of any GC given were calculated and transformed into prednisolone equivalent doses.
  8. ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein; DAS28ESR3: Disease activity score based on 28 joint count (swollen and tender joints) and ESR MHAQ: Modified health assessment questionnaire; DMARDs: Disease modifying anti-rheumatic drugs; GC: Glucocorticosteroids.